Patients and Methods We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival.

Results CEGT did not extend survival; the median survival time was 81.9 months (95% Cl, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95% Cl, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95% Cl, 0.76 to 2.39; P =.31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95% Cl, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard ratio of 0.397 (95% Cl, 0.20 to 0.78).

Conclusion CEGT does not prolong survival in women with early-stage breast cancer. (C) 2004 by American Society of Clinical Oncology.